Table 1 Baseline Characteristics of Patients with metastatic melanoma treated in low vs. high immunotherapy prescribing hospitals between 2011 and 2015
From: Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Low prescribing Hospital N = 997 (53.5%) | High prescribing Hospital N = 866 (46.5%) | p-value | |
|---|---|---|---|
Age, n (%) | < 0.001 | ||
≤ 30 | 19 (1.9) | 21 (2.4) | |
31–40 | 41 (4.1) | 66 (7.6) | |
41–50 | 98 (9.8) | 105 (12.1) | |
51–60 | 181 (18.2) | 211 (24.4) | |
61–70 | 286 (28.7) | 240 (27.7) | |
71–80 | 205 (20.6) | 149 (17.2) | |
81–90 | 167 (16.8) | 74 (8.6) | |
Gender, n (%) | 0.430 | ||
Female | 300 (30.1) | 277 (32.0) | |
Male | 697 (69.9) | 589 (68.0) | |
Race, n (%) | 0.743 | ||
White | 963 (96.6) | 832 (96.1) | |
Black | 13 (1.3) | 15 (1.7) | |
Other | 21 (2.1) | 19 (2.2) | |
Year of Diagnosis, n (%) | 0.481 | ||
2011 | 188 (18.9) | 176 (20.3) | |
2012 | 186 (18.7) | 164 (18.9) | |
2013 | 186 (18.7) | 182 (21.0) | |
2014 | 213 (21.4) | 175 (20.2) | |
2015 | 224 (22.5) | 169 (19.5) | |
Charlson Deyo Index, n (%) | < 0.001 | ||
0 | 740 (74.2) | 723 (83.5) | |
1 | 183 (18.4) | 110 (12.7) | |
2 | 50 (5.0) | 24 (2.7) | |
≥ 3 | 24 (2.4) | 9 (1.0) | |
Primary Site, n (%) | 0.337 | ||
Head and Neck | 81 (8.1) | 96 (11.1) | |
Trunk | 146 (14.6) | 119 (13.7) | |
Extremities | 120 (12.0) | 108 (12.5) | |
overlapping | 650 (65.2) | 543 (62.7) | |
Histology, n (%) | 0.035 | ||
Melanoma, NOS | 874 (87.6) | 701 (81.0) | |
Nodular | 49(4.9) | 76 (8.8) | |
Lentigo | 5 (0.5) | 14 (1.6) | |
Superficial spreading | 25 (2.5) | 33 (3.8) | |
Acral lentiginous | 2 (0.2) | 9 (1.0) | |
other | 42 (4.2) | 33 (3.8) | |
Metastatic stage, n (%) | 0.020 | ||
M1, NOS | 89 (8.9) | 41 (4.7) | |
M1a | 136 (13.6) | 110 (12.7) | |
M1b, lung | 160 (16.1) | 105 (12.1) | |
M1c, visceral | 463 (46.4) | 530 (61.2) | |
Brain involvement | 149 (14.9) | 80 (9.2) | |
Ulceration, n (%) | 0.333 | ||
No ulceration | 199 (20.0) | 193 (22.3) | |
Ulceration present | 135 (13.5) | 135 (15.6) | |
unknown | 663 (66.5) | 538 (62.1) | |
Breslow depth (continuous) | 0.559 | ||
Insurance, n (%) | < 0.001 | ||
Private | 318 (31.9) | 415 (47.9) | |
Medicare | 476 (47.7) | 315 (36.4) | |
Medicaid | 102 (0.2) | 55 (6.4) | |
Other Government | 18 (1.8) | 10 (1.2) | |
No insurance | 75 (7.5) | 26 (3.0) | |
unknown | 8 (0.8) | 45 (5.2) | |
Income*, n (%) | 0.021 | ||
≥ $ 63,000+ | 319 (32.0) | 395 (45.6) | |
$ 48,000 – 62,999 | 278 (27.9) | 238 (27.5) | |
$ 38,000 – 47,999 | 248 (24.9) | 164 (18.9) | |
< $ 37,000 | 147 (14.7) | 68 (7.9) | |
unknown | 5 (0.5) | 1 (0.1) | |
Education*,**, n (%) | < 0.001 | ||
≥ 21% | 174 (17.5) | 84 (9.7) | |
13–20.9% | 250 (25.1) | 172 (19.9) | |
7–12.9% | 347 (34.8) | 290 (33.5) | |
< 7% | 223 (22.4) | 319 (36.8) | |
unknown | 3 (0.3) | 1 (0.1) | |
Great Circle Distance, n (%) | < 0.001 | ||
< 12.5mi | 531 (53.3) | 268 (31.0) | |
12.5–49.9mi | 352 (35.1) | 347 (40.1) | |
≥ 50mi | 112 (11.2) | 250 (28.9) | |
unknown | 2 (0.2) | 1 (0.1) | |
Facility Location, n (%) | 0.017 | ||
Northeast | 121 (12.1) | 289 (33.4) | |
South | 509 (51.1) | 171 (19.8) | |
Midwest | 90 (9.0) | 129 (14.9) | |
West | 222 (22.3) | 199 (23.0) | |
unknown | 55 (5.5) | 78 (9.0) | |
Facility Type, n (%) | < 0.001 | ||
Academic | 324 (34.4) | 651 (82.6) | |
CCCP | 472 (50.1) | 113 (14.3) | |
INCP | 146 (15.5) | 24 (3.1) | |
County, n (%) | 0.637 | ||
Metro | 838 (84.1) | 753 (87.0) | |
Urban | 116 (11.6) | 89 (9.9) | |
Rural | 18 (1.8) | 8 (0.9) | |
unknown | 25 (2.5) | 19 (2.2) | |